Syntax Bio is a biotechnology research company headquartered in Chicago, Illinois, focused on synthetic biology. The company utilizes its proprietary Cellgorithm CRISPR-based platform to program stem cells and accelerate the development of next-generation organoids and cell-derived therapies.
Subscribe to see Syntax Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Syntax Bio is a drug discovery company headquartered in Chicago, United States. It has raised at least $29.4M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $14.4M in June 2026. Xcout tracks 4 named people at Syntax Bio, including John Craighead (Chief Executive Officer).
As of 16 November 2026. Source: Xcout Intel.
At least $29.4M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $14.4M | — | |
| — | $15M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Syntax Bio's closest competitors — see the full list of competitors and alternatives →
Cassidy Bio is an AI-first biotechnology company founded in 2024 and based in Israel that is developing a programmable platform for gene editing. The company utilizes a genomic foundation model powered by artificial intelligence to design safer and more scalable gene editing therapies across various guides, editors, and delivery contexts.
Coding Bio is an Oxford-based biotechnology company that combines a high-throughput wet lab and machine learning platform to screen, build, and deliver fully-assembled modular therapies like CARs and BiTEs.
Orbital Therapeutics is a biotechnology company developing RNA medicines, with a focus on engineered circular RNA and delivery technologies. Its programs are intended to address diseases that may benefit from durable, programmable protein expression, serving patients and healthcare providers through potential therapeutic products.
COUR Pharmaceuticals is a clinical-stage biotechnology company headquartered in Evanston, Illinois, founded in 2015. The firm focuses on reprogramming the immune system to develop novel treatments for autoimmune diseases.
Vivacelle Bio, Inc. is a Chicago-based developmental-stage biotechnology company pioneering innovative intravenous fluid therapies for treating conditions like sepsis and organ failure.
Automera is an early-stage biotechnology research company headquartered in Singapore. The company focuses on the development of novel therapeutics through autophagy-based targeted protein degradation.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Syntax Bio? Suggest a correction · Work at Syntax Bio? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.